Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2020 | Story Andre Damons | Photo Supplied
Heinrich Janse van Rensburg’s is a 5th year medical student from the University of the Free State whose photo was highly commended at the Imperial College London’s Global Creative Competition: Medical Student Responses to COVID-19.

A late-night photo taken through a window at the Pelonomi hospital by a final-year medical student from the University of the Free State (UFS) was highly commended at the first Global Creative Competition: Medical Student Responses to COVID-19.

The competition, held by the Imperial College London, received more than 600 entries from more than 52 countries. The competition was held to bring together the global community of medical students to submit their creative responses to COVID-19 and to provide a platform for them to reflect on their personal and professional experiences during this challenging time.

Medical students from around the world could enter in two categories; visual and literary, and the winners were announced during a Global Awards Ceremony on 14 October.

Meaning behind the photo

Heinrich Janse van Rensburg’s late -night photo highlights the economic inequality that persists in South Africa. The photo was taken from the Pelonomi Hospital which is located in Heidedal, Bloemfontein, and shows the old, forsaken Dutch Reformed church in the foreground, shacks in the background with smoke billowing from the dwellings, where up to six people live in one room trying to stay warm during winter. They are built so close to each other that there can be no talk of effective social distancing.

According to Janse van Rensburg the theme of inequality in the South African milieu is further shown in the striking contrast between light and dark in the picture. “And now, with the COVID-19 pandemic placing a massive burden on an already struggling healthcare system the inequality is even more visible,” says Janse van Rensburg.

 

Janse van Rensburg’s late-night photo taken from the Pelonomi Hospital in Heidedal, Bloemfontein, shows the economic inequality that persists in South Africa. The photo was highly commended at the Imperial College London’s Global Creative Competition for Medical Student Responses to COVID-19.


A little shocked 

He was a little shocked when he heard his photograph was highly commended. Janse van Rensburg says: “Imperial College London is a big institution and being an international competition I did not really expect a lot. There were participants from over 52 countries, and having seen some of the works that were submitted it feels special to be one of the students being noticed.”

Janse van Rensburg, who has never considered doing art, heard about the competition through the Faculty of Health Sciences platforms during lockdown level 5. He saw it as an opportunity to reflect, which has become even more imperative in times like these.

He says he does not go searching for art, but “notices” it from being conscious – something he thinks is important in medicine and life.

Value of creativity in promoting mental well-being

Dr Lynette van der Merwe, undergraduate medical programme director, School of Clinical Medicine, congratulated Janse van Rensburg, saying this commendation in an international competition underscores his talent and the value of creativity in promoting mental well-being.

“Heinrich’s artwork and showcase precisely what we aspire to develop in our exceptional UFS doctors-in-training: a professional with self-awareness, empathy and humanity.

“We initiated a Mental Health Awareness initiative and art competition in the School of Clinical Medicine in 2018 to promote creative expression as a means of supporting students’ mental health. Heinrich has won awards with his creative contributions every year, exhibiting his imaginative ability.”

Surgery and photography

Janse van Rensburg says he has always loved beautiful things and the meaning people attach to art is a good way to communicate that. He has applied for an internship at the Mitchells Plain hospital for when he completes his studies at the end of this year and is thinking of specialising in reconstructive or pediatrics surgery. Besides that, he would like to tap into his creative side and continue with the photography.

  • Watch the video of the winners here

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept